Skip to main content

Table 3 Adverse Events in the Patients with Adult NKTCL (n = 33)

From: PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity

Common adverse event I II III IV n (%)
Systemic reactions
 Allergic reaction 0 0 0 0 0 (0.0)
 Drug fever 0 0 0 0 0 (0.0)
 Infection 2 1 1 0 4 (12.1)
Hyperglycemia 3 0 0 0 3 (9.1)
Coagulation function
 Decreased fibrinogen 14 1 0 0 15 (45.5)
 Prolonged APTT      a19(57.6)
 Prolonged PT      a9 (27.3)
 Thrombosis 0 1 0 0 1 (3.0)
 Hemorrhage 0 0 0 0 0 (0.0)
Blood system
 Neutropenia 2 2 7 14 25 (75.8)
 Anemia 8 3 1 0 12 (36.4)
 Thrombocytopenia 5 2 1 0 8 (24.2)
Gastrointestinal tract
 Increase in ALT/AST 17 2 3 0 22 (66.7)
 Increase in bilirubin 11 0 0 0 11 (33.3)
 Pancreatitis 0 0 0 0 0 (0.0)
 Vomiting 4 4 0 0 8 (24.2)
 Diarrhea 0 0 1 0 1 (3.0)
Respiratory system
 Cough 0 0 0 0 0 (0.0)
 Chest tightness 0 0 0 0 0 (0.0)
 Bronchial spasm 0 0 0 0 0 (0.0)
Cardiovascular system
 Arrhythmia 0 0 0 0 0 (0.0)
 Hypotension 0 0 0 0 0 (0.0)
 Cardiac insufficiency 0 0 0 0 0 (0.0)
Nervous system
 Headache 0 0 0 0 0 (0.0)
 Insomnia 0 0 0 0 0 (0.0)
 Mental change 0 0 0 0 0 (0.0)
Urinary system
 Renal damage 0 0 0 0 0 (0.0)
 Urine color change 0 0 0 0 0 (0.0)
Other events 1 1 0 0 2 (6.0)
  1. Other events included hair loss in 2 cases. aAdverse events not graded in the NCI CTCAE classification